Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Robbins LLPDid You Lose Money Investing in Fractyl Health, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against GUTSShareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Fractyl Health, Inc. (NASDAQ: GUTS) securities between January 13, 2025 and January 29, 2026 (the "Class Period"). Fractyl is a metabolic therapeutics company that develops therapies for the treatment of type 2 diabetes ("T2D") and obesity.The complaint alleges that Fractyl...
- Everest Medicines Strengthens Its Cardiovascular Portfolio with CARDAMYST(R) Approved for the Conversion of Acute Symptomatic Episodes of PSVT to Sinus Rhythm in Adults in ChinaHONG KONG, Sept 3, 2026 - Everest Medicines today announced that China’s National Medical Products Administration (NMPA) has approved CARDAMYST(R) (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As Everest's first innovative therapy approved in the cardiovascular field, CARDAMYST further expands the Company‘s cardiovascular portfolio. The approval marks another important milestone in the execution of Everest's commercialization strategy and reinforces the Company's capability to bring innovative therapies to patients in China. CARDAMYST (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. Treatment effects observed as early as five minutes after administration, with nearly two-thirds of patients achieving conversion to sinus rhythm within 30 minutes, reducing the need for emergency medical interventions and filling a critical gap in out-of-hospital, self-administered treatment options for acute symptomatic episodes of PSVT in China. PSVT is a type of tachyarrhythmia characterized by the sudden onset and termination of episodes of rapid, regular heart rhythm. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China. During episodes, the heart rate spike is unpredictable and may last several hours. The rapid heart rate often causes disabling severe palpitations, shortness of breath, chest discomfort, dizziness or lightheadedness, and distress, forcing patients to limit their daily activities. The management of acute PSVT episodes in China has long relied primarily on hospital-based emergency care, highlighting the need for an on-demand treatment option that patients can self-administer outside of healthcare settings. “The approval of CARDAMYST addresses a critical unmet need by introducing the first innovative therapy that enables patients to self-administer treatment for acute PSVT episodes in China,” said Professor Changsheng Ma, M.D., Principal Investigator of the Phase III JX02002 study, Director of Cardiology Department at Beijing Anzhen Hospital, and President of the Chinese Society of Cardiology, Chinese Medical Association, “Both the global pivotal Phase III RAPID trial and the China Phase III JX02002 study demonstrated its rapid onset, robust efficacy, and favorable safety profile. We believe this innovative therapy has the potential to transform the treatment paradigm for acute PSVT episodes by enabling timely, patient-initiated treatment, reducing the need for emergency medical intervention, and ultimately improving patients' quality of life.” “The approval of CARDAMYST marks an important milestone, introducing the first out-of-hospital, patient-administered treatment option for acute PSVT episodes in China,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As the only innovative therapy currently available that enables patients to self-administer treatment for PSVT episodes outside of healthcare settings, CARDAMYST offers a new on-demand treatment option. With treatment effects observed as early as five minutes after administration, CARDAMYST enables patients to manage episodes outside of a healthcare setting, giving them greater control over their condition and potentially reshaping the treatment paradigm for PSVT in China. Leveraging our proven commercialization capabilities, we look forward to accelerating the launch of CARDAMYST in China to address the significant unmet needs of patients with PSVT and realize its long-term clinical and societal value." The approval of CARDAMYST was supported by the global pivotal Phase III RAPID trial and the Phase III JX02002 study in China. Both studies met their primary endpoints. The RAPID trial achieved its primary endpoint with 64% of participants who self-administered etripamil (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared to 31% on placebo (N=85) (HR = 2.62; p<0.001). The study results were published in The Lancet in 2023. In the JX02002 study, among participants with PSVT episodes (N=84), a greater number of patients receiving etripamil achieved conversion to sinus rhythm within 30 minutes, compared with placebo (N=84) (hazard ratio [HR] = 3.002; p=0.0005). In December 2025, CARDAMYST was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST is also in Phase III clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), with positive Phase II results supporting its advancement. CARDAMYST has the potential to benefit more than 12 million patients in China, including those with PSVT and AFib-RVR. The approval of CARDAMYST(R) further strengthens Everest Medicines’ presence across the cardiovascular, kidney, and metabolic (CKM) disease areas and broadens its innovative product portfolio. As the Company’s first innovative drug approved in the cardiovascular disease field, CARDAMYST(R) also complements the Company’s existing portfolio and creates opportunities for portfolio synergies. Leveraging its established commercialization capabilities, Everest Medicines will move forward with the launch of CARDAMYST(R) in China while advancing its development in additional cardiovascular indications, including AFib-RVR, to bring new treatment options to more patients with cardiovascular disease.
- CTF Life's 'Aspiration Ride' Transforms Hong Kong's Iconic 'Ding Ding' into a Moving Celebration of AspirationsHONG KONG, Sept 3, 2026 - CTF Life unveiled the “Aspiration Ride”, a month-long themed tram inspired by its latest brand campaign, “Your Aspiration. Our Aspiration.”. Running from 2 to 29 September, the themed tram transforms one of the city’s most beloved means of transport into a moving celebration of the aspirations that inspire Hongkongers at every stage of life. The activation forms part of a broader integrated campaign that combines outdoor advertising and digital storytelling featuring influencers to illustrate how aspirations evolve through different life stages, inspiring audiences to reflect on their journeys and the support behind them. For many Hongkongers, the tram is more than part of the daily commute. It is a living theatre of everyday life: childhood journeys by the window, first jobs, new beginnings and quiet reflections between stops. For more than a century, the city’s “ding ding” has travelled through changing streetscapes and generations, silently keeping pace as aspirations have taken shape, evolved and been pursued. Building on this shared journey, the “Aspiration Ride” invites people across all life stages to reflect on their ambitions and the support that helps turn them into possibilities. Officially unveiled at the launch ceremony on 2 September, the tram features a vibrant exterior design filled with colourful illustrations and more than 100 aspirations submitted by citizens through CTF Life’s social media platforms. Set against a backdrop of Chinese composition paper, the messages bring personal aspirations to life across the city, transforming the tram into a moving canvas of dreams and possibilities. CTF Life’s management team also added their own aspirations to the tram exterior, joining a shared display of ambitions, both modest and momentous, that give life a sense of purpose. “Hong Kong’s tramways have long been woven into the city’s collective memory, carrying generations of people and the stories that have shaped their journeys,” said Ruby Kwan, Marketing Director, CTF Life. “Every aspiration tells a story. Some stay with us for life, while others evolve as we move through different stages and embrace new possibilities. Yet each has the power to inspire us to grow, explore and move forward with purpose. “The ‘Aspiration Ride’ is a key element of an integrated campaign designed to bring the conversation around aspirations into everyday life. Through outdoor advertising, creator collaborations and digital storytelling, we hope to encourage people to reflect on what matters most to them and recognise that every aspiration represents a future worth pursuing. At CTF Life, we are committed to walking alongside our customers through every life stage across our four brand pillars of Wellbeing, Growth, Health and Wealth, helping them pursue their aspirations with confidence by providing the right support along the way.” The campaign also includes a tram-shelter advertisement on Paterson Street in Causeway Bay, extending the activation into one of Hong Kong’s busiest districts. A series of promotional videos featuring influencers, CTF Life Planner, and other members of the community, each representing different life stages and perspectives, will further support post-launch awareness. Through personal stories spanning childhood curiosities, evolving ambitions and creative passions, the videos illustrate that aspirations do not follow a single path. Instead, they show how encouragement, preparation and support can help turn them into possibilities. Through digital and social media storytelling, these relatable journeys will invite audiences across the city to reflect on their own aspirations and the people who help make them possible. In a city that is always in motion, the “Aspiration Ride” offers a gentle reminder that it is worth looking up from the journey and remembering what set it in motion. Aspirations may differ in scale and destination, but each represents a meaningful reason to keep moving forward. Through the campaign, CTF Life aims to spark conversations on how aspirations evolve throughout life, and to encourage people to pursue them with confidence, knowing they are supported every step of the way. CTF Life’s Marketing Director Ruby Kwan hopes the “Aspiration Ride” can encourage people to reflect on what matters most to them CTF Life’s management team also added their own aspirations to the tram exterior CTF Life’s management team officiates the ribbon-cutting ceremony to mark the official launch of the “Aspiration Ride” “Aspiration Ride” commences its citywide journey with over 100 aspirations submitted through CTF Life’s social media platforms
- Uwill, IncNew Survey Finds Colleges Inheriting Students With Greater Mental Health Needsnew Uwill survey, high school seniors report emotional strain as colleges prepare for the touchscreen generation. — The next generation of college students are expected to arrive on campus with greater emotional strain and different expectations...
- Legacy HealthcareLegacy Healthcare Welcomes U.S. Congressional Legislation Proposing 12-Year Market Exclusivity for US FDA Newly Approved Botanical DrugsThe "ADVANCING BOTANICAL DRUG DEVELOPMENT ACT OF 2026," introduced on Aug 27, 2026, would provide 12-year post-approval market exclusivity to encourage investment in FDA-regulated botanical drugs innovation EPALINGES, Switzerland, Sept. 3, 2026 -- Legacy Healthcare welcomes...
- Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth ConferenceProfound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.
- SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense CompanySRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today is providing shareholders with an update on its portfolio company ARMR Sciences (“ARMR”), a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, such as fentanyl, from its CEO, Collin Gage.
- Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)Clinical outcomes from 264 PH-LHD patients demonstrate a 51% reduction in the risk of clinical worsening, a 35.5% decrease in recurrent clinical events, and sustained concurrent improvements in functional capacity, supporting the multi-dimensional therapeutic benefits of the Pulmonary...
- CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for the treatment of mild to moderate atopic dermatitis (“AD”) on 2 September 2026. The drug registration certificate was obtained on 3 September 2026. The product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- 60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference60 Degrees Pharma (Nasdaq: SXTP) will present on demand at H.C. Wainwright beginning Sept. 11 and hold 1 x 1 investor meetings Sept. 14–16 in New York.
- Northway BiotechFIRST IN THE BALTICS: NORTHWAY BIOTECH OPENS €61 MILLION CELL THERAPY AND PERSONALIZED MEDICINE CDMO IN VILNIUSBuilding on more than 22 years of CDMO experience across biologics and advanced therapies, Northway Biotech is significantly expanding its development and manufacturing capacity with a new 3,500 sq. m facility featuring up to 20 independent cGMP manufacturing lines and first customer...
- Quince Therapeutics, Inc.Quince Therapeutics to Participate in September 2026 Investor ConferencesQuince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026: